This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Atkins, M. B. Articles by McDermott, D. Search for Related Content PubMed PubMed Citation Articles by Atkins, M. B. Articles by McDermott, D.

Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma

¹ Beth Israel Deaconess Medical Center, ² Dana-Farber Cancer Institute; and ³ Dana-Farber/Harvard Cancer Center Renal Cancer Program, Boston, Massachusetts

Immunoreactive cytokines have been the mainstay of treatment of renal cancer for the past 15 years. Most research has focused on interferon alpha (IFN-) and interleukin 2 (IL-2). IFN- has been shown in Phase III studies to produce a modest survival advantage over inactive or non-IFN-containing regimens. Its general tolerability, multiple proposed mechanisms of action, and familiarity have prompted IFN- to be studied in combination with a variety of agents with potential activity against renal cell carcinoma. These various studies may justify an increased role for IFN- in the treatment of renal cancer in the foreseeable future. High-dose bolus IL-2 remains the only treatment for stage IV renal cancer approved by the United States Food and Drug Administration. Food and Drug Administration approval was granted in 1992 based on the ability of this agent to produce durable complete responses in a small number of patients. Unfortunately, the toxicity, expense, and restricted accessibility of high-dose IL-2 make it a poor standard. Regimens involving lower doses of IL-2 either alone or in combination with IFN- have generally produced fewer tumor regressions of less overall quality. Recent efforts have focused on trying to identify factors predictive of response to IL-2 therapy so that this treatment could be limited to those most likely to benefit.

This article has been cited by other articles:

				B. Escudier, C. Szczylik, T. E. Hutson, T. Demkow, M. Staehler, F. Rolland, S. Negrier, N. Laferriere, U. J. Scheuring, D. Cella, et al. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., March 10, 2009; 27(8): 1280 - 1289. [Abstract] [Full Text] [PDF]

				I. D. Davis, B. K. Skrumsager, J. Cebon, T. Nicholaou, J. W. Barlow, N. P. H. Moller, K. Skak, D. Lundsgaard, K. S. Frederiksen, P. Thygesen, et al. An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma Clin. Cancer Res., June 15, 2007; 13(12): 3630 - 3636. [Abstract] [Full Text] [PDF]

				N. Suciu-Foca, N. Feirt, Q.-Y. Zhang, G. Vlad, Z. Liu, H. Lin, C.-C. Chang, E. K. Ho, A. I. Colovai, H. Kaufman, et al. Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients J. Immunol., June 1, 2007; 178(11): 7432 - 7441. [Abstract] [Full Text] [PDF]

				M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]

				J.-S. Jin, A. Chen, D.-S. Hsieh, C.-W. Yao, M.-F. Cheng, and Y.-F. Lin Expression of Serine Protease Matriptase in Renal Cell Carcinoma: Correlation of Tissue Microarray Immunohistochemical Expression Analysis Results with Clinicopathological Parameters International Journal of Surgical Pathology, January 1, 2006; 14(1): 65 - 72. [Abstract] [PDF]